J. Keith Joung

J. Keith Joung is a leading innovator in the fields of gene and epigenetic editing. He is currently the Robert B. Colvin, M.D. Endowed Chair in Pathology and a Pathologist at Massachusetts General Hospital (MGH) and a Professor of Pathology at Harvard Medical School. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH. Joung has been a pioneer in the development of important technologies for targeted gene editing and epigenetic editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the MGH Research Scholar Award, an NIH R35 MIRA (Maximizing Investigators Research Award), election into the American Association of University Pathologists and designation as a “Highly Cited Researcher” for five consecutive years (2016-2020) by Thomson Reuters/Clarivate Analytics. Joung has co-founded and advises multiple biotechnology companies, including Beam Therapeutics, Editas Medicine, Pairwise Plants, SeQure Dx, and Verve Therapeutics. He holds a Ph.D. in genetics from Harvard, an M.D. from Harvard Medical School.